Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q4 FY25 results · Jan–Mar 2025
Dr. Lal Path Labs reported revenue from operations of ₹602.60 crore (up 10.5% from Q4 FY24) and net profit of ₹155.50 crore (up 81.2% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 602.60 | 545.40 | +10.5% | 596.70 | +1.0% |
| Other income | 25.80 | 18.40 | +40.2% | 25.10 | +2.8% |
| Total income | 628.40 | 563.80 | +11.5% | 621.80 | +1.1% |
| Profit before tax | 153.40 | 119.90 | +27.9% | 138.30 | +10.9% |
| Net profit for the period | 155.50 | 85.80 | +81.2% | 98.10 | +58.5% |
| Attributable to shareholders of the company | 154.80 | 84.50 | +83.2% | 96.70 | +60.1% |
| EPS, basic (₹) | 18.57 | 10.13 | +83.3% | 11.60 | +60.1% |
| Net margin (%) | 25.8 | 15.7 | 16.4 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 577.20 | 479.00 | +20.5% | 528.10 | +9.3% |
| Other income | 25.20 | 15.90 | +58.5% | 29.50 | −14.6% |
| Total income | 602.40 | 494.90 | +21.7% | 557.60 | +8.0% |
| Profit before tax | 144.90 | 120.50 | +20.2% | 151.20 | −4.2% |
| Net profit for the period | 148.40 | 89.50 | +65.8% | 114.50 | +29.6% |
| EPS, basic (₹) | 17.80 | 10.73 | +65.9% | 13.74 | +29.5% |
| Net margin (%) | 25.7 | 18.7 | 21.7 |
Consolidated
- Filed with BSE
- 25 Apr 2025, 19:15 IST
- Board meeting
- 25 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 Apr 2025, 19:15 IST
- Board meeting
- 25 Apr 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE